Related Experiment Videos
Probable ticlopidine-induced cholestatic hepatitis
L J Cassidy1, B G Schuster, L S Halparin
1Department of Pharmacy, St. Paul's Hospital, Vancouver, British Columbia, Canada.
The Annals of Pharmacotherapy
|January 1, 1995
Summary
Ticlopidine can cause cholestatic hepatitis, a liver injury. Patients should monitor for jaundice and discontinue the drug if symptoms arise.
Area of Science:
- Hepatology
- Clinical Pharmacology
Background:
- Ticlopidine is an antiplatelet medication.
- Drug-induced liver injury is a significant concern in clinical practice.
Observation:
- A 76-year-old male developed painless jaundice three weeks after initiating ticlopidine therapy.
- The patient had no prior history of liver disease.
Findings:
- The jaundice and abnormal liver enzymes resolved after discontinuing ticlopidine.
- A review of literature identified seven additional cases of ticlopidine-induced cholestatic hepatitis.
Implications:
- While routine liver enzyme monitoring is not advised, patients should be aware of potential liver injury symptoms.
- Prompt discontinuation of ticlopidine and medical consultation are crucial if signs of liver injury appear.